A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants

Launched by REGENERON PHARMACEUTICALS · Jul 24, 2023

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • 1. Has a body mass index between 18 and 32 kg/m\^2
• • 2. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and electrocardiograms (ECGs) performed at screening and/or prior to administration of initial dose of study drug, as defined in the protocol
• • 3. Has normal blood pressure (BP) and pulse rate readings, as defined in the protocol
• • 4. Difference between semi-recumbent systolic blood pressure (SBP) measurements in left and right arm less than 20 mmHg at screening visit
• Key Exclusion Criteria:
• • 1. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as assessed by the investigator that may confound the results of the study or poses an additional risk to the participant by study participation
• • 2. History, in the past 2 years of a diagnosis of hypertension, symptomatic hypotension (BP \<90/50 mmHg with associated symptoms), symptomatic orthostatic hypotension, postural orthostatic tachycardia syndrome, syncope, or clinically significant cardiac arrhythmia
• • 3. Presents any concern to the study investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study
• • 4. Was hospitalized (ie, \>24 hours) for any reason within 30 days of screening
• • 5. Is a current smoker or former smoker, including e-cigarettes, who stopped smoking within 3 months prior to screening
• • NOTE: Other protocol defined inclusion / exclusion criteria apply